A few words about us

The Genesius company is connected with the scientific discipline called synthetic biology, which constitutes a combination of molecular biology, genetic engineering and chemistry of nanostructures.


We offer constructs consisting of nucleic acids (DNA/RNA), and Human AID recombinant protein which can be used in the process of creating the end product, e.g. the medicinal product.

How to order

Should you have any doubts on how to order our products, contact us +48 600 605 857 / info@genesius.pl.

Choose a team of experienced specialists and modern equipment...

Genesius Laboratory and its products

The Genesius laboratory is located in the suburbs of Poznan, within the High Technology Incubators Complex at 46H Rubiez street. This localization offers the company state-of-the art technological platforms, scientific equipment and support services. Our team constitutes highly qualified scientists/practitioners in the fields of molecular biology, genetic engineering, and nanostructure chemistry.

Our offer is dedicated to both academic researchers as well as biotechnological and pharmaceutical companies that are exploring the area of genetics. Our products - constructs consisting of nucleic acids, both DNA and RNA - may be subject to an infinite variety of drugs and medications. Therefore, we are open to cooperation with scientific organizations to implement various innovative systems and products we have already designed or constructed. We are also open to take part in any programme enabling exploring our knowledge in synthetic biology.

We are pleased to inform, that we introduced to the market a completely new product: Human AID recombinant protein. Human activation-induced cytidine deaminase (hAID) fully active recombinant fusion protein is partially purified from E. coli containing a recombinant plasmid harboring the human AID gene. Activation-induced cytidine deaminase, also known as AICDA and AID, is a 24 kDa enzyme which in humans is encoded by the AICDA gene. It creates mutations in DNA by deamination of cytosine base, which turns it into uracil (which is recognized as a thymine). In other words, it changes a C:G base pair into a U:G mismatch. The cell's DNA replication machinery recognizes the U as a T, and hence C:G is converted to a T:A base pair. During germinal center development of B lymphocytes, AID also generates other types of mutations, such as C:G to A:T. The mechanism by which these other mutations are created is not well-understood. AID, which recently has been implicated in active DNA demethylation looks pretty much this way:

The protein is currently thought to be the master regulator of secondary antibody diversification. It is involved in the initiation of three separate immunoglobulin (Ig) diversification processes:

  1. Somatic hypermutation (SHM), in which the antibody genes are minimally mutated to generate a library of antibody variants, some of which with higher affinity for a particular antigen and any of its close variants
  2. Class switch recombination (CSR), in which B cells change their expression from IgM to IgG or other immune types
  3. Gene conversion (GC) a process that causes mutations in antibody genes of chickens, pigs and some other vertebrates.

AID has been shown in vitro to be active on single-strand DNA, and has been shown to require active transcription in order to exert its deaminating activity. The involvement of Cis-regulatory factors is suspected as AID activity is several orders of magnitude higher in the immunoglobulin "variable" region than other regions of the genome that are known to be subject to AID activity. This is also true of artificial reporter constructs and transgenes that have been integrated into the genome. A recent publication suggests that high AID activity at a few non-immunoglobulin targets is achieved when transcription on opposite DNA strands converges due to super-enhancer activity.

To encourage you to purchase our product we are open to the possibility of sending you a free sample of the protein. This shall give you an opportunity to test whether the quality and purity of the human AID recombinant protein is sufficient for your work. 

our partners

Genesius Sp. z o.o., ul. Rubież 46H, 61-612 Poznań, Poland
NIP: 9721244814, REGON: 302470730, KRS: 0000494790

© 2013-2017. All rights reserved.